Crescent Biopharma to present preclinical data from CR-001

Crescent Biopharma (CBIO) announced that preclinical data from CR-001, its PD-1 x VEGF bispecific antibody being developed for solid tumors, will be presented at the Society for Immunotherapy of Cancer’s, SITC, 40th Annual Meeting being held November 7-9, 2025 in National Harbor, Maryland. “These data highlight the cooperative mechanism of CR-001 and its ability to reduce tumor growth in vivo, reinforcing its potential as a next generation immuno-oncology therapy,” said Jan Pinkas, Ph.D., chief scientific officer of Crescent. “We are on track to advance CR-001 into the clinic and plan to initiate our global Phase 1 trial in patients with solid tumors in the first quarter of 2026.”